Current and historical daily PE Ratio for Celadon Pharmaceuticals PLC (
LSE:CEL
) from 2022 to May 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Celadon Pharmaceuticals PLC stock (LSE:CEL) PE ratio as of May 22 2024 is 0.
More Details
Celadon Pharmaceuticals PLC (LSE:CEL) PE Ratio (TTM) Chart
Celadon Pharmaceuticals PLC (LSE:CEL) PE Ratio (TTM) Historical Data
View and export this data going back to 2022. Start your Free Trial
Total 538
- 1
- 2
- 3
- 4
- 5
- 6
| Celadon Pharmaceuticals PLC PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-22 | At Loss | 2024-03-15 | At Loss |
| 2024-05-21 | At Loss | 2024-03-14 | At Loss |
| 2024-05-20 | At Loss | 2024-03-13 | At Loss |
| 2024-05-17 | At Loss | 2024-03-12 | At Loss |
| 2024-05-16 | At Loss | 2024-03-11 | At Loss |
| 2024-05-15 | At Loss | 2024-03-08 | At Loss |
| 2024-05-14 | At Loss | 2024-03-07 | At Loss |
| 2024-05-13 | At Loss | 2024-03-06 | At Loss |
| 2024-05-10 | At Loss | 2024-03-05 | At Loss |
| 2024-05-09 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-03 | At Loss | 2024-02-28 | At Loss |
| 2024-05-02 | At Loss | 2024-02-27 | At Loss |
| 2024-05-01 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
Celadon Pharmaceuticals PLC (LSE:CEL) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Celadon Pharmaceuticals PLC
ISIN : GB00BDQYGP38
Description
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers